Poliomyelitis: all 227 studies

Page 1 of 3. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine AdsorbedRecruitingNCT07891104Phase 1/2
• Study of BK1803 in Healthy InfantsNot yet recruitingNCT07793513Phase 3
• Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy AdultsRecruitingNCT07688369Phase 1
• Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus VaccineRecruitingNCT07457060Phase 4
• Phase IV Clinical Study of sIPV Administration in Adolescent and Adult PopulationsRecruitingNCT07354269Phase 4
• the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L VaccinesNot yet recruitingNCT07338851
• A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated InfantsRecruitingNCT07010822Phase 3
• Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines EvaluationRecruitingNCT06895486Phase 2
• Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of AgeNot yet recruitingNCT06618196Phase 2
• Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis VaccinesRecruitingNCT06137664Phase 1/2
• A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy AdultsNot yet recruitingNCT05952596Phase 1
• Study of a Novel Type 3 Oral Poliomyelitis Vaccine in PanamaRecruitingNCT05654467Phase 2
• A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2CompletedNCT05677256Phase 4Results posted
• Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in InfantsCompletedNCT05033561Phase 3Results posted
• A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine CandidatesCompletedNCT04544787Phase 2Results posted
• Study of Novel Types 1 and 3 Oral Poliomyelitis VaccinesCompletedNCT04529538Phase 1Results posted
• Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)CompletedNCT04481191Phase 3Results posted
• Confirmatory Study of BK1310 in Healthy InfantsCompletedNCT03891758Phase 3Results posted
• A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio VaccineCompletedNCT03554798Phase 2Results posted
• Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed AdultsCompletedNCT03430349Phase 1Results posted
• A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPVCompletedNCT03239496Phase 3Results posted
• IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and AdultsTerminatedNCT03092791Phase 1/2Results posted
• Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryCompletedNCT02853929Phase 4Results posted
• A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in LithuaniaCompletedNCT02582255Phase 4Results posted
• A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of AgeCompletedNCT02580201Phase 4Results posted
• Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis VaccineCompletedNCT02434770Phase 3Results posted
• Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryCompletedNCT02422264Phase 4Results posted
• Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy InfantsCompletedNCT02096263Phase 3Results posted
• Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in JapanCompletedNCT02005536Phase 4Results posted
• Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at BirthCompletedNCT01948193Phase 3Results posted
• Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected SubjectsCompletedNCT01686503Phase 2Results posted
• Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus VaccinesCompletedNCT01616693Phase 4Results posted
• Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese ToddlersCompletedNCT01577732Phase 3Results posted
• Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)CompletedNCT01453998Phase 2Results posted
• Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy InfantsCompletedNCT01444781Phase 3Results posted
• Regulatory Post-Marketing Surveillance Study for TETRAXIM™CompletedNCT01437423Phase 4Results posted
• Glutathione and Health With Post-Polio SyndromeCompletedNCT01402570Not applicableResults posted
• Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™CompletedNCT01358825Phase 4Results posted
• Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) VaccineCompletedNCT01353703Phase 3Results posted
• Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted AdultsCompletedNCT01323959Phase 4Results posted
• Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated ToddlersCompletedNCT01323647Phase 3Results posted
• Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib VaccineCompletedNCT01309646Phase 3Results posted
• Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)CompletedNCT01248884Phase 2Results posted
• Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old ChildrenCompletedNCT01245049Phase 3Results posted
• A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American InfantsCompletedNCT01177722Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DoseCompletedNCT01171989Phase 2Results posted
• Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy ToddlersCompletedNCT01106092Phase 2Results posted
• Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in RussiaCompletedNCT01094171Phase 4Results posted
• Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy InfantsCompletedNCT01090453Phase 2Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ VaccineCompletedNCT01086423Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ VaccineCompletedNCT01021293Phase 3Results posted
• Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgeCompletedNCT00970307Phase 2Results posted
• Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)CompletedNCT00964028Phase 3Results posted
• Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in InfantsCompletedNCT00937404Phase 1Results posted
• Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in ToddlersCompletedNCT00920439Phase 3Results posted
• Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.TerminatedNCT00871741Phase 2Results posted
• Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.CompletedNCT00871000Phase 3Results posted
• Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean InfantsCompletedNCT00831311Phase 2Results posted
• Immunogenicity and Safety of Adacel Polio VaccineCompletedNCT00797511Phase 3Results posted
• Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in InfantsCompletedNCT00753649Phase 4Results posted
• Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™CompletedNCT00654901Phase 3Results posted
• Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio VaccineCompletedNCT00635128Phase 4Results posted
• Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib VaccineCompletedNCT00627458Phase 2Results posted
• Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old ChildrenCompletedNCT00611559Phase 4Results posted
• Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same VaccinesCompletedNCT00463437Phase 3Results posted
• Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)CompletedNCT00432042Phase 3Results posted
• Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy InfantsCompletedNCT00404651Phase 3Results posted
• Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®CompletedNCT00355121Phase 2Results posted
• Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)CompletedNCT00337428Phase 3Results posted
• Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy InfantsCompletedNCT00325156Phase 4Results posted
• Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B VaccineCompletedNCT00325143Phase 3Results posted
• Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis VaccineCompletedNCT00304265Phase 4Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean InfantsCompletedNCT00303316Phase 3Results posted
• Effects of Virtual Walking on Chronic Pain and Psychological Distress for Individuals With Severe Mobility ImpairmentActive, not recruitingNCT07820618Not applicable
• Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)CompletedNCT07297186Phase 3
• The Impact of 'Digital Strolling' on Depression and Quality of Life of People With Severe Mobility ImpairmentCompletedNCT07073144Not applicable
• A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary SeriesActive, not recruitingNCT06947499Phase 2/3
• A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old InfantsCompletedNCT06752174Phase 3
• A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and ToddlersActive, not recruitingNCT06577298Phase 1/2
• Booster Dose of sIPV Co-administered With MMR and HepA-I.CompletedNCT06442449Phase 4
• Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different ManufacturersCompletedNCT06346834Phase 4
• Evaluation of Fatigue Severity, Mood, and Quality of Life in Post-Polio SyndromeCompletedNCT06162104
• A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy AdultsCompletedNCT06101173Phase 1
• Immunogenicity of After Primary Immunization and Booster Immunization of sIPVActive, not recruitingNCT06058429
• High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care PartnersCompletedNCT05951985Not applicable
• A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV VaccineCompletedNCT05850364Phase 3
• Community Engagement and Conditional Incentives to Accelerate PolioCompletedNCT05721274Not applicable
• Effect of Digital Payment to Campaign Health Workers on Vaccination CoverageStatus unknownNCT05684081Not applicable
• Study of a Novel Type 1 Oral Poliomyelitis Vaccine in BangladeshCompletedNCT05644184Phase 2
• Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus VaccineCompletedNCT05460377Phase 4
• Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary SeriesCompletedNCT05457946Phase 2/3
• A Safety Study of Sabin Inactivated Poliovirus Vaccine in InfantsCompletedNCT05432141Phase 4
• Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in InfantsCompletedNCT05431933Phase 3
• Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old InfantsCompletedNCT05386810Phase 3
• Intradermal Fractional Dose IPV (fIPV) in Combination With dmLTActive, not recruitingNCT05327426Phase 1
• Physical Activity in People With Sequelae of PoliomyelitisStatus unknownNCT05303545
• Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio VaccineWithdrawnNCT05166031Phase 3
• Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus VaccineCompletedNCT05163561Phase 3
• Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19CompletedNCT05083039
• An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four DosesCompletedNCT04989231

← Poliomyelitis overview